Shutting down a gene called PRMT5 stopped metastatic estrogen receptor-positive (ER+) breast cancer cells from growing after they acquired resistance to a standard therapy known as CDK4/6 inhibitors, UT Southwestern Medical ...
20 hours ago
0
15
Mayo Clinic researchers have used a new approach to chemotherapy to more than double the typical survival rate for patients with stomach cancer and peritoneal metastasis, which is cancer that has spread to the lining of the ...
Apr 23, 2024
0
1
Atrial fibrillation (Afib), a common type of arrhythmia that is on the rise in people under the age of 65, is more dangerous in this increasingly younger population than previously thought, according to a new study published ...
Apr 22, 2024
0
1
Women with triple-negative breast cancer, and high levels of immune cells in the tumors, have a lower relapse risk after surgery, even without chemotherapy, according to a recent study published in JAMA.
Apr 17, 2024
0
5
New research from the University of Pittsburgh explains why metastatic uveal melanoma is resistant to conventional immunotherapies and how adoptive therapy, which involves growing a patient's T cells outside the body before ...
Apr 16, 2024
0
55
Scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC) have identified the mechanisms through which anthracyclines, a widely used class of anticancer drugs, damage the hearts of patients receiving this ...
Apr 16, 2024
0
0
Artificial intelligence has been found to improve the outcome of patients with voice box cancer, which is a step closer to personalized treatment, new research has revealed.
Apr 15, 2024
0
1
Patient prognosis and treatment response prediction are key factors in treating ovarian cancer, which is characterized by the lowest survival rate among gynecological cancers. Consequently, there is strong demand for a more ...
Apr 15, 2024
0
0
Adjuvant alectinib improves disease-free survival compared with platinum-based chemotherapy among patients with resected ALK-positive non-small cell lung cancer (NSCLC), according to a study published in the April 11 issue ...
Apr 13, 2024
0
1
The U.S. Food and Drug Administration has approved Abecma (idecabtagene vicleucel) as a personalized CAR T-cell therapy for triple-class exposed relapsed or refractory multiple myeloma.
Apr 10, 2024
0
1
